Improvement of the Frequencer ability to treat COVID‑19 patients who require airway clearance
Dymedso, a Canadian-based medical device SME specialized in pulmonary disease therapeutic and treatment equipment is a patented pioneer in using sound (acoustics) to treat patients requiring airway clearance such as Cystic Fibrosis COPD and the coronavirus family, SARS, MERS and naturally the COVID-19. The company’s Frequencer® has FDA, Health Canada, European CE, and UL (North America, Europe, Australia, and New Zealand) approvals and has been used in hospitals since 2010 with an established base of more than 600 devices in operations around the globe.
Dymedso continues to explore ways to improve its product by conducting research aiming development products to treat wider range of patients requiring airway. The goal of Dymedso (Richard Boudreault) and the University of Waterloo (Yuri Leonenko) partnership is to investigate the possibilities to improve performance of Frequencer and improve the product’s ability to treat COVID‑19 patients who require airway clearance.
Currently Dymedso is increasing the supply of its devices to Montreal hospitals to treat COVID‑19 patients. Most patients using the Frequencer will never require an ICU bed nor a ventilator.
